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Genetically evoked deﬁciency of collagen VII causes 
dystrophic epidermolysis bullosa (DEB)—a debilitat-
ing disease characterized by chronic skin fragility and 
progressive ﬁbrosis. Removal of exons carrying frame-
disrupting mutations can reinstate protein expression 
in genetic diseases. The therapeutic potential of this 
approach is critically dependent on gene, protein, and 
disease intrinsic factors. Naturally occurring exon skip-
ping in COL7A1, translating collagen VII, suggests that 
skipping of exons containing disease-causing mutations 
may be feasible for the treatment of DEB. However, 
despite a primarily in-frame arrangement of exons in the 
COL7A1 gene, no general conclusion of the aptitude of 
exon skipping for DEB can be drawn, since regulation 
of collagen VII functionality is complex involving fold-
ing, intra- and intermolecular interactions. To directly 
address this, we deleted two conceptually important 
exons located at both ends of COL7A1, exon 13, con-
taining recurrent mutations, and exon 105, predicted to 
impact folding. The resulting recombinantly expressed 
proteins showed conserved functionality in biochemical 
and in vitro assays. Injected into DEB mice, the proteins 
promoted skin stability. By demonstrating functionality 
of internally deleted collagen VII variants, our study pro-
vides support of targeted exon deletion or skipping as a 
potential therapy to treat a large number of individuals 
with DEB.
Received 22 February 2016; accepted 3 May 2016; advance online  
publication 7 June 2016. doi:10.1038/mt.2016.92
INTRODUCTION
Dystrophic Epidermolysis Bullosa (DEB) is an orphan disorder 
caused by mutations in the gene COL7A1 encoding collagen VII—
a large extracellular protein and the main component of anchoring 
fibrils.1 Because anchoring fibrils are crucial for attachment of the 
dermal-epidermal basement membrane to the underlying papil-
lary dermis, DEB is characterized by chronic skin fragility leading 
to mechanically induced blistering and formation of longstanding 
wounds. Further complications arise from progressive soft tissue 
fibrosis that, in the most severe forms of the disease, results in for-
mation of mitten-like deformities of hands and feet, and high pro-
pensity for development of aggressive squamous cell carcinomas.2 
DEB is currently incurable but development of gene-, protein-, 
and cell-based therapies is actively being pursued,3 with topical 
therapies showing the best prospect of translation into the clinics. 
Importantly, DEB is in its most severe forms a systemic disorder 
with large surfaces inaccessible to topical treatment and thus, a 
systemic therapy would be most beneficial for patients. However, 
at present, the size of the COL7A1 gene and the lack of vectors 
with high specific skin tropism remain the principal limitations 
for the development of systemic cDNA-mediated gene therapy 
approaches for this disease.4–7
To overcome challenges related to classical gene therapy, 
development of systemic exon skipping–based strategies to cor-
rect the reading frame is promising. Duchene muscular dystro-
phy (DMD) is a progressive neuromuscular disorder caused by 
mutations in the DMD gene.8 These mutations lead to diminished 
levels of functional dystrophin.9 Like COL7A1, the DMD gene is 
composed of a multitude of exons10,11 and over 60% of mutations 
are frame disrupting.9 Strategies targeting mutated exons have 
been successfully developed for DMD by using antisense oligo-
nucleotides (AON) inducing transient dystrophin expression. In 
addition, more recently the Dmd reading frame was permanently 
restored in vivo in mice after CRISPR/Cas9-mediated excision 
of exon 23.12–14 These approaches aim to remove the disease-ini-
tiating mutation to restore the reading-frame that will promote 
expression of internally deleted proteins. The hope is that the 
resulting protein retains full or partial functionality, thereby pro-
viding protection against disease progression.15
Case reports suggest that skipping of mutated exons in some 
patients results in less severe DEB,16–19 supporting the potential 
of excision of faulty exons to treat the disease. In addition, one 
study provided cautious optimism of AON-based therapy for 
DEB.5 However, skipping of in-frame exons that carry causal 
mutations does not unequivocally improve symptoms. It may in 
fact exaggerate the disease by rendering proteins with severely 
impaired  functionality.20 Consequently, detailed analysis on the 
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protein level is needed to determine the functionality of internally 
deleted protein variants. Eventually, the benefit of exon skipping 
or removal therapies depends on efficacy of the therapy, func-
tionality of the protein and diseases progression. For example, 
although, there is a clear and irrefutable correlation of dystrophin 
expression and improved outcome of the disease,15 shortage of 
information of the functionality of internally deleted dystrophin 
variants may have delayed translation of AON-based therapies 
for DMD into the clinics.15,21 The complex folding, the multimeric 
arrangement, and the multiple interaction partners of collagen 
VII make the effect of removal of amino acids encoded by single 
exons from collagen VII hard to predict. Thus, a first step for 
development of therapies aiming to skip or remove exons con-
taining causal mutations is to demonstrate that collagen VII vari-
ants resulting from in-frame exon deletion remain functional. In 
order to do so, an efficient method to generate and to character-
ize the functional consequence of deletion of any in-frame exon 
from COL7A1 is needed.
Here, we investigated the feasibility of DEB therapies based 
on exon skipping or gene editing to remove exons carrying causal 
mutations. We confirmed that disease relevant exons in COL7A1 
could be targeted by AONs. Subsequently, we designed a strategy 
to generate collagen VII variants lacking amino acids encoded by 
specific exons and to determine the level of functionality of these 
recombinantly expressed collagen VII variants by molecular, cel-
lular, and in vivo assays. As proof-of-concept we chose to generate 
DEB patient-relevant collagen VII variants resulting from deletion 
of COL7A1 exon 13 or 105 (named collagen VII Δ13 and Δ105, 
respectively). Altogether, our study provides support that targeted 
removal of exons containing causal mutations can be used to treat 
a large number of individuals with DEB.
RESULTS
In silico analysis of COL7A1 gene reveals that the 
majority of exons can be skipped or removed without 
disrupting the reading frame
COL7A1, the gene encoding for collagen VII, is composed of 118 
exons.22 In silico analysis of this gene revealed that 92% (107/118) 
of exons can be individually skipped without disturbing the open 
reading frame of COL7A1 or modifying more than one amino 
acid (Figure 1). Importantly, none of the single amino acid modi-
fications leads to creation of a stop codon. Every exon coding for 
parts of the collagenous domains can be skipped without causing 
a frame-shift. Since the collagenous domain is mainly responsible 
of the fibrillar structure of collagen VII, it is likely that deletion of 
several Gly-X-Y repeats will not drastically impair protein-protein 
interactions but it may have structural consequences. This could be 
a special consideration for exons encoding a number of amino acids 
not dividable by three, since their removal will interrupt the Gly-
X-Y repeat. However, as the collagenous domain of collagen VII is 
already imperfect, it is challenging to predict the outcome of deletion 
of such exons. All exons that cannot be removed without disturbing 
the open reading frame are located in the NC1 and NC2 domains of 
collagen VII. Importantly, both domains also contain exons that can 
be removed without changing more than one amino acid or creating 
a stop codon. The NC1 and NC2 domains are responsible for medi-
ating skin-stabilizing binding to laminin 332 and collagen IV,23–26 
and for homodimerization to initiate anchoring fibril formation,27 
Figure 1 In silico analysis of COL7A1 exon organization. The ﬁgure presents COL7A1 exons, organized as a jigsaw puzzle-like structure to illustrate 
which exons can be skipped without disrupting the open reading frame or changing more than one amino acid. Boxes with red line represent exons 
that cannot be skipped without evoking a reading frame shift. All such exons are located in noncollagenous domain 1 (NC1, in blue) and 2 (NC2, in 
green). The remaining exons correspond to the collagenous domain (in orange), which can be divided into two parts (P1 and P2) based on the pres-
ence of a noncollagenous hinge region in the middle of the protein. Localization of von Willebrand factor A (VWFA-1 and -2), FN type III and Kunitz 
inhibitor (Kunitz) domains are indicated as well.
Noncollagenous region 1 (NC1) Noncollagenous region 2 (NC2)
Unskippable exon
Collagenous domain 2 (P2)
Collagenous domain 1 (P1)
Noncollagenous hinge region
Molecular Therapy vol. 24 no. 7 jul. 2016 1303
© The American Society of Gene & Cell Therapy
Exon-skipped Collagen VII
respectively. Since these interaction sites have not been precisely 
mapped, the consequences of removing exons coding for parts of the 
NC1 or NC2 domains cannot be easily predicted. In conclusion, the 
specific exon organization of COL7A1 suggests that exon-skipping 
therapy and gene editing to remove faulty exons are attractive thera-
peutic approaches for DEB. However, careful analyses of the protein 
variants resulting from specific exon removal are a prerequisite to 
fully determine the therapeutic potential of such therapies.
Removal of amino acids encoded by exon 13 or 105 
does not impair folding
To start addressing the feasibility of the above-mentioned 
approaches to treat DEB, we first developed a robust strategy for 
deletion of any exon from COL7A1 cDNA. We used this strategy to 
delete exon 13 and 105, respectively (Supplementary Figure S1). 
Exon 13 is one of the most recurrent mutated COL7A1 exons,28 
and thus investigation of the functionality of collagen VII lacking 
the amino acids encoded by exon 13 is of high medical interest. 
Mutations in exon 105, which encodes for 27 amino acids, cause a 
severe disease manifestation.28 In addition, the two selected exons 
encode parts of two different functional domains, i.e., exon 13 
encodes a part of the NC1 domain and exon 105 encodes a part of 
the carboxyl-terminal end of the collagenous domain. A deletion 
within the NC1 domain might impair the binding to interaction 
partners. Although the position-dependent effect of amino acid 
substitutions and deletions in collagen VII is elusive,29 it is known 
that the collagen VII triple helix folds from the C to the N ter-
minus.30 Thus, in analogy with naturally occurring causal muta-
tions for other collagens,31,32 the impact on folding after removal of 
amino acids in the collagenous domain can therefore be assumed 
to be greater the more C-terminally the deletion occurs.
Before detailed characterization of the functionality of the inter-
nally deleted collagen VII variants resulting from exon skipping or 
deletion, we first tested that these exons could be efficiently targeted. 
Toward this end, we designed AONs against human COL7A1 exons 
13 and 105 and showed that efficient skipping was feasible in cultured 
dermal fibroblasts (Figure 2). AONs based on the same chemistry 
have previously been shown to reach skin after systemic administra-
tion in concentrations sufficient to restore protein synthesis,33 and 
we chose fibroblasts because they would be the main targets in a sys-
temic therapy. After having established that both exons were ame-
nable to exon skipping, we then proceeded to construct expression 
Figure 2 Antisense oligonucleotides (AON) can induce skipping of exon 13 and 105 in dermal ﬁbroblast. RT-PCR on RNA extracted from dermal 
ﬁbroblast treated with 250 or 500 nmol/l of AONs designed against exon 13 (a) or 105 (c) shows efﬁcient skipping of the respective exons. For both 
exons ampliﬁcation of the region surrounding exon 13 (exon 12 to 14) or exon 105 (exon 102 to 106) reveals an additional lower band correspond-
ing to an amplicon lacking exon 13 (144 bp) or 105 (81 pb), respectively. Sanger sequencing then conﬁrms the precise skipping of exon 13 (b) or 
105 (d). White asterisk indicates heteroduplex DNA.
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vectors containing COL7A1 lacking the nucleotides corresponding 
to exon 13 or 105. HEK293 cells were subsequently transfected with 
these constructs. Reverse transcription polymerase chain reaction 
(RT-PCR) on RNA isolated from transfected cells first confirmed 
expression of COL7A1 mRNA lacking exon 13 or 105 (Figure 3a). 
Further, as shown in Figure 3a, immunostaining with collagen VII 
antibodies revealed that the deletion of exon 13 or 105 did not inter-
fere with protein expression or secretion.
We then expressed wild-type (WT) and Δ13 or Δ105 col-
lagen VII in the presence of ascorbic acid to allow stable triple 
helix formation and purified the proteins from the media.34 We 
compared the ability of collagen VII molecules to withstand 
proteolytic digestion with trypsin in order to gain information 
about the folding of the collagen VII variants, because properly 
folded collagen triple helices are resistant to trypsin digestion.35,36 
The WT and the two collagen VII variants were protected from 
trypsin proteolysis at 30 °C, while boiling prior to digestion com-
pletely abolished the protection (Figure 3b). A natural collagen 
VII mutant carrying a glycine substitution at amino acid position 
1776 (G1776R) was used as negative control, and in accordance 
with previous findings, showed no thermal stability at 30 °C.35 
Relatively subtle reduction in the thermal stability is connected to 
forms of dominantly inherited DEB35,37; therefore, we more care-
fully evaluated the thermal stability of the triple helical structure 
of collagen VII by performing limited trypsin digestion along a 
temperature gradient.34 No significant changes were observed in 
the thermal stability of collagen VII Δ13 or Δ105 in comparison 
to the WT protein (Figure 3c). For the WT and the two collagen 
VII variants, we observed a mean melting temperature of around 
42 °C, which is in agreement with previous experiments.35,38 
Taken together, our data confirm that removal of the amino acids 
encoded by exon 13 or 105 does not interfere with the essential 
ability to fold into stable collagen VII triple helices.
Collagen VII Δ13 and Δ105 retain their ability to bind 
collagen IV
Binding of collagen VII to interaction partners in the dermal-
epidermal basement membrane is essential for skin stability. It 
has been demonstrated that the collagen VII NC1 domain inter-
action with collagen IV and laminin 332 is site-specific.24 Thus, 
it is important to assess the ability of the collagen VII variants 
to interact with these two binding partners. This was especially 
important for Δ13 collagen VII, which lacks amino acids in the 
NC1 domain. We performed solid-phase binding assays to test the 
binding capacity of collagen VII variants. These assays revealed 
no significant difference between the interaction of WT, Δ13 or 
Δ105 collagen VII with collagen IV or laminin 332 (Figure 4 and 
Supplementary Figure S2). In contrast, only a weak interaction 
was observed with collagen VII denatured by boiling, while the 
interaction of the glycine substituted mutant G1776R with col-
lagen IV was preserved but significantly reduced (WT: 7.6 nmol/l 
± 1.1; Δ13: 5.1 nmol/l ± 1.4; Δ105: 5.4 nmol/l ± 1.3; G1776R: 
Figure 3 Collagen VII variants can form stable triple helices. (a) The upper panel shows by RT-PCR on mRNA isolated from HEK cells expressing 
WT, Δ13, or Δ105 collagen VII that exon 13 or 105 are absent in the Δ13 and Δ105 construct carrying cells, respectively. The lower panel shows col-
lagen VII immunostaining of HEK 293 cells expressing WT, Δ13 or Δ105 collagen VII. (b) Limited trypsin digestion at 30 °C with or without pre-boiling 
of the samples conﬁrms that deletion of exon 13 or 105 in COL7A1 does not disturb the thermal stability of the collagen VII collagenous domain. 
(c) Detailed thermal stability analysis reveals that the Tm of all collagen VII variants (WT, Δ13, or Δ105) is approximately 42 °C.
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23 nmol/l ± 5.4). Because the mutation G1776R occurs in the col-
lagenous domain, it is not surprising that this misfolded glycine 
substituted mutant is still able to bind collagen IV. Nevertheless, 
this result also shows that mutations in the collagenous domain 
can affect the binding strength to the interaction partners of the 
NC1 domain. Importantly, these data show that Δ13 and Δ105 
collagen VII retain the ability to bind the epidermal basement 
membrane with similar strength as WT collagen VII.
Collagen VII variants support ﬁbroblast adhesion and 
migration in vitro
It is known that collagen VII can support keratinocyte and fibro-
blast adhesion and migration in vitro,39,40 and that collagen VII 
derived from DEB patients supports these events to a lesser 
extent.41 Therefore, we tested the ability of Δ13 or Δ105 colla-
gen VII to promote cell adhesion and migration of fibroblasts. 
No adhesion was observed with bovine serum albumin (BSA), 
whereas, in agreement with previous findings, fibronectin (FN) 
and WT collagen VII efficiently supported fibroblast adhesion.41 
Importantly, Δ13 and Δ105 collagen VII supported adhesion of 
fibroblasts equally well as WT collagen VII (Figure 5a). We then 
analyzed the effect on cell migration in in vitro wound healing 
and in direct cell migration assays. From both assays, it was evi-
dent that Δ13 and Δ105 collagen VII indeed supported fibroblast 
migration to a similar degree as WT collagen VII (Figure 5b,c). 
Altogether, these results show that absence of the amino acids 
encoded by exon 13  or 105 does not interfere with fibroblast 
adhesion and migration. This suggests that skipping or permanent 
deletion of these exons will still allow production of functional 
collagen VII variants in a cellular context.
Injection of collagen VII variants in RDEB mice leads 
to deposition at the dermal-epidermal junction
To test the in vivo functionality of the collagen VII variants, we 
used the Col7a1 hypomorphic mouse. This mouse maintains 
a residual 10% expression of WT collagen VII (Figure 6a),42 
which is sufficient to rescue the mice from lethality but leads to 
a phenotype resembling the most severe human phenotype, i.e., 
generalized severe recessive DEB.42 To assess the functionality 
of collagen VII variants resulting from exon deletion, we intra-
dermally injected Col7a1 hypomorphic mice with WT, Δ13 or 
Δ105 collagen VII. One day after the injection the mice were sac-
rificed and skin close to the injection site was collected, sectioned, 
and stained with an antibody specifically detecting human col-
lagen VII.36 Injection of WT collagen VII resulted in deposition 
of  collagen VII at the dermal-epidermal junction zone (DEJZ) 
(Figure 6b), as previously described.43 In order to discriminate 
unspecific retention of collagen VII, we also injected heat dena-
tured WT collagen VII. The denatured collagen VII was present 
at the injection site but was unable to translocate to the DEJZ 
(Figure 6b). Importantly, injection of Δ13 and Δ105 collagen VII 
resulted in a clear deposition at the DEJZ, which was comparable 
to the deposition of WT collagen VII (Figure 6c—white arrows). 
We then investigated if injections of the collagen VII variants 
could promote skin stabilization. Interestingly, whereas the skin 
from vehicle-injected Col7a1 hypomorphic mice displayed clearly 
visible dermal-epidermal microblisters (Figure 6d), only very 
limited dermal-epidermal separation was observed after injec-
tion of WT, Δ13, and Δ105 collagen VII, respectively (Figure 6d). 
Although the time elapsed between the injection and the analysis 
(1 day) is too short to allow formation of well-developed anchor-
ing fibrils, the injected collagen VII was nonetheless already able 
to promote dermal-epidermal cohesion. The analysis suggests a 
skin stabilizing effect of collagen VII even outside mature anchor-
ing fibrils and shows that the primary physiological function of 
both internally deleted collagen VII variants is maintained in vivo.
DISCUSSION
One approach to treat genetic diseases is to restore protein expres-
sion by removing exons carrying causal mutations, either via exci-
sion on the DNA level or via exon skipping-based therapies on 
the pre-mRNA level. The unique gene structure of COL7A1 makes 
development of such therapies to treat DEB highly interesting. 
We here provide solid evidence that collagen VII can withstand 
deletion of amino acids provided by individual exons without 
significant impairment of functionality. Recently, it was reported 
that natural skipping of exon 15 resulted in drastic attenuation of 
the phenotypic severity of DEB.19 A milder phenotype was also 
observed for natural skipping of exon 87 (refs. 16,17) and exon 
19 (ref. 18) Although removal of some exons will certainly lead to 
nonfunctional collagen VII, these observations, together with our 
Figure 4 Collagen VII variants retain ability to bind collagen IV. 
Variable concentrations of WT, denatured WT, Δ13, or Δ105 collagen 
VII were used (0.27 to 70 nmol/l) to analyze binding to 500 ng immo-
bilized collagen IV. The data were normalized to the maximal signal 
recorded and were collected from three independent experiments. Heat 
denatured WT collagen VII shows a weak and nonsaturable binding and 
the collagen VII mutant G1776R shows a saturable interaction but with 
weaker afﬁnity than for WT collagen VII. In contrast Δ13 and Δ105 col-
lagen VII display similar Kd values as WT collagen VII indicating that 
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findings, provide evidence for the feasibility of exon skipping or 
exon removal therapy to treat DEB.
Among the options that are available to achieve therapeu-
tic exon skipping for DEB, development of AON therapy would 
likely result in the fastest translation into use in the clinics. We 
here show that AONs can be designed against exons 13 and 105 
to robustly promote exon skipping. Nevertheless, the develop-
ment of AON therapies is still hampered by low cellular uptake 
and exon skipping efficiency.44 However, it has been shown that 
they can reach the skin after systemic delivery in concentrations 
sufficient to restore protein synthesis.33 It also has to be consid-
ered that the effect of AONs is transient and limited by the protein 
lifetime. (Bornert, O, Peking, P, Bremer, J, Koller, U, van den 
Akker, PC, Aartsma-Rus, A,  et al. (2016). RNA-based therapies 
for genodermatoses. Submitted.). In the case of collagen VII the 
in vivo half-life is around 1 month indicating that frequent treat-
ment cycles with AONs would be needed for significant protec-
tion against frictional challenges.45 To overcome these challenges, 
development of permanent exon skipping-based strategies are of 
high interest. U7 small nuclear RNA (snRNA), usually involved 
in histone pre-mRNA 3’-end processing, can be used as a splicing 
modulator.46–48 Very recently, permanent restoration of the Dmd 
reading frame resulting in dystrophin expression was achieved 
in vivo in a Duchenne mouse model. In the mouse, AAV-mediated 
Figure 5 Collagen VII variants support ﬁbroblast adhesion and migration. Tissue culture plates were coated with bovine serum albumin, FN, WT, 
Δ13, or Δ105 collagen VII to study cell adhesion and migration. (a) Fibroblast adhesion assay. Two hours after seeding, ﬁbroblasts were ﬁxed and 
stained with crystal violet. After cell lysis, quantiﬁcation was performed by recording the absorbance at 550 nm. Data are expressed as the percentage 
of adhesion. (b) Fibroblast wound healing assay. Dotted line represents the original wound edge. (c) Direct migration assay. Dotted line represents 
the original border. These results suggest that the lack of amino acids resulting from deletion of exon 13 or 105 does not interfere with the ability to 
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muscular delivery of CRISPR/Cas9 allowed excision of exon 
23 that harbored the causal mutation.12–14 It is a clear asset that 
CRISPR/Cas9-mediated gene editing promotes permanent repair, 
which would limit treatment cycles. However, multiple safety con-
cerns surround the approach and there is a shortage of suitable 
vectors with high skin tropism. Nevertheless, the development of 
gene-editing techniques for permanent restoration of collagen VII 
expression should be considered as an attractive therapy approach 
for DEB. Thus, there are multiple options to remove faulty mes-
sages encoded by exon sequences, and although these techniques 
still need improvement and optimization, we do not view them as 
the principal limitation of exon skipping or exon removal strate-
gies. What will ultimately determine therapeutic success are the 
protein intrinsic properties. The internally deleted proteins result-
ing from these efforts need to remain highly functional. Therefore, 
we believe that it is imperative to analyze the functionality of such 
Figure 6 Collagen VII variants can be deposited at the dermal-epidermal junction in RDEB mice. (a) Skin tissue sections from WT and Col7a1 
hypomorphic mice immunostained for collagen VII (green). While WT skin exhibits a strong signal for collagen VII at the dermal-epidermal junction 
zone, minimal collagen VII deposition is seen in Col7a1 hypomorphic mice (white dotted line). (b) Skin sections stained for human collagen VII (green) 
after intradermal injection of Col7a1 hypomorphic mice with 25 μg of WT collagen VII and heat denatured WT collagen VII. The staining reveals that 
only correctly folded collagen VII is able to translocate to the dermal-epidermal junction after injection (white arrows). Note that the injected collagen 
VII is clearly visible in deeper dermal areas in both skin sections (white arrowheads). (c) Skin sections one day after intradermal injection of Col7a1 hypo-
morphic mice with 10 μg of WT, Δ13, and Δ105 collagen VII stained for human collagen VII (green). The staining reveals that deletion of amino acids 
encoded by exon 13 or 105 does not affect the ability of collagen VII to translocate to the dermal-epidermal junction zone compared to WT collagen 
VII (white arrows). (d) H&E staining of skin sections as in (c). The histological analysis reveals that collagen VII variants lacking amino acids encoded 
by exon 13 or 105 promote dermal-epidermal stability equally well as WT collagen VII. While vehicle injected mice show areas of dermal-epidermal 
separation (red arrows), such separations are not visible in mice which had received 10 μg of WT, Δ13, or Δ105 collagen VII. Bar = 50 μm, D = dermis, 
E = epidermis, in a and b nuclei visualized by 4′,6-diamidino-2-phenylindole (blue). White asterisks indicate autoﬂuorescence of the epidermis.
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protein variants before endeavoring into optimization of exon 
skipping or gene editing of specific exons.
A potential limitation of restored protein expression by thera-
peutic removal or skipping of exons carrying mutations is neutral-
izing immune reactions that may nullify the therapeutic benefit. As 
for all therapies aiming to restore protein expression in a genetic 
disorder, special attention needs to be placed on the immunologi-
cal response from the host to the de novo expressed protein. This is 
especially important for collagen VII, which is known to be highly 
antigenic.49 However, it has become evident that a large number 
of individuals with generalized severe DEB are mosaic and carry 
revertant skin patches that express collagen VII.50 Thus, the immune 
system of many of the prospective patients for these therapies has 
already encountered collagen VII, and accordingly immunogenicity 
to collagen VII may not be an issue. Still, it is conceivable that skip-
ping or permanent removal of specific exons, especially in the NC1 
domain can create new highly antigenic epitopes. These concerns 
can only be reliably addressed directly in patients.
Based on the results presented in this paper, we can conclude 
that skipping or excision on the DNA level of exon 13 or 105 will 
lead to production of collagen VII variants with retained in vivo 
functionality. Because DEB is a familial disease, development of 
skipping or gene-editing strategies to remove specific exons will 
only be beneficial for a small subset of patients, making these 
approaches a type of personal medicine. In comparison to tradi-
tional therapy, personal medicine is highly challenging because 
adaptation to each patient phenotype and/or genotype is an ines-
capable prerequisite. In order to optimize cost and time for the 
development of such therapy, a generic strategy is first needed to 
study the theoretical effect on the target, i.e., gene or protein. By 
a combination of molecular, cellular, and in vivo experiments, we 
have developed a robust procedure for the characterization of col-
lagen VII variants resulting from lack of faulty exons in COL7A1. 
Our method can be used as a screening assay to test the effect of any 
exon deletion from COL7A1. Importantly, this method could also 
be interesting as a tool to delineate the collagen VII interactome.
To conclude, we here show by detailed analysis of recombi-
nantly expressed internally deleted collagen VII variants that exon 
skipping–based therapy or similar gene editing approaches should 
be considered highly attractive options for treatment of DEB.
MATERIALS AND METHODS
Ethics statement. Studies using patient material were approved by the 
Ethics committee of the University of Freiburg approval number 45/03-
110631. All animal experiments were approved by the regional ethics 
review board (Regierungspräsidium Freiburg), ethical approval number 
G11/70 and G14/93. The mice were housed in a clean facility with water, 
food, and supportive nutrition ad libitum.
Antibodies. The following primary antibodies were used: rabbit anti-
NC2-10 for collagen VII P1 fragment and rabbit anti-LH7.2 for collagen 
VII NC1 domain.27,32 Secondary antibodies were Alexa Fluor 488-conju-
gated goat anti rabbit (Invitrogen, Darmstadt, Germany) and horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit (Jackson Immuno Research 
Laboratories, Newmarket, UK).
Deletion of exon in COL7A1. Extraction of cDNA encoding collagen VII 
from pcDNA3.1 was performed by digestion with NotI (5’) and EcoRI 
(3’). Small fragments of COL7A1 cDNA were obtained by digestion with 
PciI, SacII, or HincII. Fragments 3’-PciI, SacII-HincII, and HincII-5’ from 
COL7A1 cDNA containing respectively exon 1 to 25, 57 to 101 and 103 to 
117 were subcloned into pBlueScript or pUC19 vectors. Primers Exon-13-
Forward (5′-TGCGCAGCACCCAGGAGCCGGAAACTCCACTT-3′) 
and PciI-reverse-primer (5′-ACATGTATCTGTGAGCTGTGACC-3′) 
were used to amplify region after exon 13, and primers Exon-13-reverse 
(5′-GTGGAGTTTCCGGCTCCTGGGTGCTGCGC-3′) and M13FR 
(5′-GTTTTCCCAGTCACGAC-3′) the region before exon 13. Primers 
Exon-105-forward (5′-GGATCCCTGGTGACCCGGGTGAACGGGG 
AGTGAAGGGA-3′) with M13RP (5′-CAGGAAACAGCTATGAC-3′) 
and Exon-105-reverse (5′-CGGGTCACCAGGGATCCCTGCTGCACC 
AGGTTGACCCT-3′) with M13FR (5′-GTTTTCCCAGTCACGAC-3′) 
were used to respectively amplify regions after and before exon 105. Overlap 
PCR was carried out with primers M13FP and M13RP (exon 105) or M13FP 
and PciI-reverse-primer (exon 13). PCR products lacking exon 13 or 105 
were ligated together with the rest of COL7A1 cDNA in pcDNA3.1 with a 
ratio of 1 to 1 by using T4 DNA ligase (Thermo Fisher Scientific, Waltham, 
MA). All PCR reactions were performed with Phusion High Fidelity poly-
merase (Thermo Fisher Scientific, Waltham, MA) and the constructs were 
sequenced by Sanger sequencing (GATC Biotech, Konstanz, Germany). 
All Enzymes were purchased from Thermo Fisher Scientific and used 
accordingly to the manufacturer’s instruction. Plasmids were purified with 
NucleoSpin. Plasmid and DNA products were extracted from agarose gel 
with NucleoSpin gel and PCR clean-up (Macherey Nagel, Düren, Germany).
Cell culture and transfection. Fibroblasts or HEK-293 cells were cultured 
in DMEM/F12 (Life Technologies, Carlsbad, CA) medium containing 
10% fetal calf serum (Biochrome, Berlin, Germany), supplemented with 
200 mmol/l L-glutamine, and 10 mg/ml penicillin-streptomycin (both Life 
Technologies, Carlsbad, CA). HEK-293 cells were transfected with 28 μg of 
cDNA per 10-cm dish using lipofectamine 2000 (Sigma-Aldrich, St. Louis, 
MO) for COL7A1 WT and lacking exon 13 or 105 in pcDNA3.1. Cells con-
taining the transfected plasmid were selected with phleomycin (InvivoGen, 
San Diego, CA) for at least 72 hours. Expression of WT, Δ13, or Δ105 col-
lagen VII was performed in serum-free Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 50 μg/ml ascorbic acid (Fluka, Buchs, 
Switzerland). Medium was collected after 48 hours and cleared by cen-
trifugation at 3,000 rpm for 10 minutes prior purification of recombinant 
collagen VII by precipitation with ammonium sulfate (Roth, Karlsruhe, 
Germany). A concentration of 25% of ammonium sulfate was added to the 
cleared medium overnight at 4 °C under gentle agitation. Precipitated pro-
teins were collected by high speed centrifugation at 14,000 rpm for 30 min-
utes at 4 °C and resuspended in tris-buffered saline (TBS) buffer (50 mmol/l 
Tris-HCl (Roth) pH 7.4 and 150 mmol/l NaCl (Roth)) supplemented with 
10 mmol/l ethylenediaminetetraacetic acid (Serva, Heidelberg, Germany) 
and 1 mmol/l Pefabloc (Sigma-Aldrich, St. Louis, MO). Proteins were used 
immediately or stored at −70 °C for long term.
AON design and cell treatment. For design of AONs with a combined maxi-
mal predicted splicing specificity and in vivo efficiency, we used m-fold and 
HSF softwares, together with Tm calculation and RNA structure prediction 
according to established guidelines.51 After in silico analyses, we selected 
AONs with the sequence 5′-GCCUGAACGUCAUCCAAGUCG-3′ and 
5′-CUCCUUUUUCUCCUCGGAUACCAGG-3′ to target 13 and 105, 
respectively. A nonspecific AON 5′-GCUUUUCUUUUAGUUGCUGC-3′ 
was used as negative control and with the addition of a 5′-FAM 537.46 fluo-
rescent label as positive control. All AONs comprise 2′ O-methyl-modified 
bases and phosphorothioate linkages, and were synthesized and purified by 
reverse-phase high-performance liquid chromatography (Eurogentec BV, 
Liège, Belgium). Primary normal human dermal fibroblasts were trans-
fected with AON using Lipofectamine-2000 (LF) (Invitrogen, Carlsbad, 
CA). The lipid-AON complex formation was optimized to a weight:weight 
ratio of 1:1. Prior to transfection, cells were grown to 70–80% conflu-
ence, washed, and fresh Opti-MEM (Gibco, Waltham, MA) medium was 
added to the wells. Lipid-AON complexes were formed according to the 
manufacturer’s instructions and drop-wise added to the cells to a final 
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concentration of 250 or 500 nmol/l of AONs in the medium. After 6 hours 
of incubation at 37 °C and 5% CO2, the medium was removed, cells were 
washed, and complete culture medium was added.
For the analysis of exon skipping on the RNA level, RNA was isolated 
48 hours after transfection using the RNeasy Micro Kit (Qiagen). The 
medium was removed from the wells prior to addition of the lysis buffer. 
The lysates were collected in 1.5 ml tubes, vortexed for 1 minute, flash 
frozen in liquid nitrogen, and stored at −80 °C before RNA isolation was 
performed according to the manufacturer’s instructions. Following RNA 
isolation, RNA was immediately reverse transcribed using Superscript-III 
(Invitrogen) reverse transcriptase. Reverse transcription was followed by 
PCR analysis of exon 13 and 105 of the COL7A1 gene using nested PCR 
and the following primers:
• First forward exon 13: 5′-GGTGGTACTGCCCTCTGATG-3′ 
• First reverse exon 13: 5′-TCCGTTCGAGCCACGATGAC-3′ 
• Nested forward exon 13: 5′-CCGCCTCACACTCTACACTC-3′ 
• Nested reverse exon 13: 5′-AGCCACCTGGTAGGTGGTTC-3′ 
• First forward exon 105: 5′-TCAGCTGTGATCCTGGGGCCT-3′ 
• First reverse exon 105: 5′-AGGGCAGCAAGGGAGAGCCT-3′ 
• Nested forward exon 105: 5Ļ-AGGGCAGCAAGGGAGAGCCT-3′ 
• Nested reverse exon 105: 5′-TTTGTGTCCTGCCAGCCCGG-3′ 
• Sanger sequencing of amplicons was performed by GATC.
Immunoﬂuorescence staining. Cells on cover slips were fixed with ice-cold 
acetone for 5 minutes. After air-drying, cells were washed with phosphate-
buffered saline (PBS) and blocked with 0.1% BSA in PBS for 20 minutes. 
Cells were then incubated with the rabbit anti collagen VII LH7.2 antibody 
diluted at 1:2,000 in PBS with 0.1% BSA (Santa Cruz, Dallas, TX) for 1 hour. 
After washing with PBS, 1:1,000 diluted anti-rabbit Alexa488 antibody was 
added for 30 minutes. Nuclei were stained with 4′,6-diamidino-2-phenyl-
indole for 2 minutes; coverslips were wased and embedded in fluorescence 
mounting medium (Dako, Hamburg, Germany) for examination. Images 
were acquired with an Axiocam MRm camera attached to a Zeiss Axio 
Imager A1 fluorescence microscope (Carl Zeiss, Jena, Germany), processed 
using Axiovision 4.8 and ZEN2009 software (Carl Zeiss).
RNA isolation and RT-PCR. RNA was isolated from cells with NucleoSpin 
RNA isolation kit (Macherey-Nagel, Düren, Germany) according to the man-
ufacturer’s instructions and transcribed to cDNA with First Strand cDNA 
Synthesis Kit (Thermo Fisher Scientific). PCRs were performed with primers 
surrounding exon 13 or 105 and analyzed on a 2% agarose gel. The following 
primers were used: 5′-CATTGTGCGCAGCACCC-3′ and 5′-AGCAAGTGG 
AGTTTCCGGC-3′ for exon 13, 5′-AGACTCAGCTGTGATCCTGG-3′ and 
5′-CCCTTCACTCCCCGTTCAC-3′ for exon 105 (Biomer, Ulm, Germany).
Western blotting. Samples were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose 
membranes (Millipore, Darmstadt, Germany). Blocking buffer (50 mmol/l 
Tris-HCl pH 7.4, 150 mmol/l NaCl, 0.05% Tween-20 with 5% non-fat milk) 
was used to block the membranes. Blots were then incubated with the rabbit 
anti collagen VII antibodies LH7.2 or NC2-10 in blocking buffer overnight 
at 4 °C. After extensive wash with TBS-tween buffer, HRP-conjugated goat 
anti-rabbit antibody was added for 1 hour. Enhanced chemiluminescence 
prime reagent (GE Healthcare, Freiburg, Germany) was used to develop 
blots and pictures were captured using a Fusion SL system (Peqlab, Erlangen, 
Germany). Quantification was performed with Image J (NIH, Washington, 
DC) and data were analyzed with GraphPad Prism software (Graphpad, La 
Jolla, CA).
Trypsin digestion assays. Triple helical folding of collagen VII was assessed 
by limited trypsin digestion with or without preboiling of collagen VII as 
previously described.34,36 Boiled collagen VII was used as positive control 
as boiling prior trypsin digestion completely disrupts the triple helix and 
abolishes the trypsin resistance of the collagen VII collagenous domain.
Solid-phase interaction. Five hundred nanograms of collagen IV (Sigma-
Aldrich) were used to coat Nunc Maxsorp 96-well plates overnight at 4 °C. 
The next morning, wells were blocked with 0.1% BSA in PBS for 1 hour 
and various concentrations of precipitated collagen VII in TBS were then 
added for 1 hour. After extensive wash with PBS, 1:1,000 diluted rabbit 
LH7.2 antibody was added for 1 hour at room temperature. Wells were 
washed three times with PBS and HRP-conjugated goat anti-rabbit anti-
body diluted at 1:10,000 was added. Finally, SigmaFast OPD tablet (Sigma-
Aldrich) was used for detection of peroxidase activity and plate was read 
at 450 nm on infinite M200 plate reader (Tecan, Männedorf, Switzerland).
Cells adhesion and migration assays. Nunc F Untreated 96-wells plates 
were used for adhesion assays (Thermo Fisher Scientific). Wells were 
coated with 100 ng of BSA, FN, WT collagen VII, Δ13 or Δ105 collagen 
VII in PBS. After overnight incubation at 4 °C, wells were blocked with 
0.1% BSA in PBS for 1 hour. Then 100,000 fibroblasts were seeded per well 
and the plate was incubated for 2 hours at 37 °C. After washing with PBS, 
fibroblasts were fixed with 100% methanol for 5 minutes and stained with 
0.1% crystal violet for 20 minutes. Pictures were taken after extensive wash 
with PBS and cells lysis was performed with 1% acetic acid. Quantification 
was made by reading the absorbance at 550 nm and data were analyzed 
using GraphPad Prism software.
Migration assays were performed by using silicone inserts (ibidi, 
Martinsried, Germany). The dishes were first coated with BSA, FN, 
WT collagen VII, Δ13 or Δ105 collagen VII in PBS as describe above. 
After seeding of 100,000 fibroblasts, plates were incubated at 37 °C until 
confluence. The insert was removed and pictures were taken at different 
time points to follow cell migration. Quantification was made using Image 
J and data were analyzed with the GraphPad Prism software.
Collagen VII injection in Col7a1 hypomorphic mice. Col7a1 hypomorphic 
mice were identified by hemorrhagic blisters at mechanically challenged 
sites, as previously described.37 Prior to injections, the back skin of Col7a1 
hypomorphic mice was carefully cleaned and disinfected. 10 or 25 μg of 
WT, Δ13 or Δ105 collagen VII were diluted in 30 μl vehicle and injected 
intradermally with a 27 G needle (B.Braun Melsungen, Germany). 24 hours 
after injection mice were sacrificed and skin samples were taken for fur-
ther analysis. Skin sections were fixed in acetone, blocked, and stained with 
primary and secondary antibodies, counterstained with 4′,6-diamidino-
2-phenylindole, and mounted in Fluorescence Mounting Medium (Dako). 
Images were acquired with an Axiocam MRm camera attached to a Zeiss 
Axio Imager A1 fluorescence microscope (Carl Zeiss, Jena, Germany) and 
processed using the Axiovision 4.9 and the ZEN2012 softwares (Carl Zeiss). 
For H&E stainings the skin was fixed in neutral buffered ready-to-use 10% 
formalin solution (Sigma-Aldrich) and embedded in paraffin. The sections 
were stepwise deparaffinized, rehydrated, and stained with hematoxylin 
(Sigma-Aldrich) for 2.5 minutes, thereafter they were decolorized in acid 
alcohol for 2 seconds and the pH was increased by tap water for 10 min-
utes. The sections were counterstained with 0.1% eosin (Sigma-Aldrich) 
for 30 seconds and dehydrated through increasing alcohol concentrations. 
Eventually, sections were embedded in mounting medium (Sigma-Aldrich).
Statistical analysis. Statistical analysis was performed with the GraphPad 
Prism software using Student’s unpaired t-test, a P value of < 0.05 was con-
sidered statistically significant.
SUPPLEMENTARY MATERIAL
Figure S1. Generic strategy for exon deletion in COL7A1 cDNA.
Figure S2. Collagen VII variants retain ability to bind laminin 332.
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